Dr Christoph Alexander Bergmann, MD | |
4934 Pecan Dr, Belden, MS 38826-8715 | |
(662) 840-1708 | |
Not Available |
Full Name | Dr Christoph Alexander Bergmann |
---|---|
Gender | Male |
Speciality | Radiology - Diagnostic Radiology |
Location | 4934 Pecan Dr, Belden, Mississippi |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1699717439 | NPI | - | NPPES |
00120594 | Medicaid | MS | |
009908720 | Medicaid | AL | |
300096927 | Other | MS | RAILROAD MEDICARE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2085R0202X | Radiology - Diagnostic Radiology | 16289 (Mississippi) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Christoph Alexander Bergmann, MD 4934 Pecan Dr, Belden, MS 38826-8715 Ph: (662) 840-1708 | Dr Christoph Alexander Bergmann, MD 4934 Pecan Dr, Belden, MS 38826-8715 Ph: (662) 840-1708 |
News Archive
A new study published in the January issue of CHEST establishes that patients with chronic obstructive pulmonary disease face heightened risks of death, critical illness, and hospitalization if they develop the flu and demonstrates the beneficial effects of influenza vaccination.
In Caesarean deliveries the placenta is usually removed by hand or by a technique known as 'cord traction'. A recent systematic review by Cochrane Researchers shows that cord traction poses less risk to the mother than manual removal.
Research conducted by Suresh Alahari, PhD, Professor of Biochemistry and Genetics at LSU Health New Orleans School of Medicine, has found that metformin, a commonly prescribed drug for Type 2 Diabetes, may be effective in treating cancers that lack a protein called Nischarin.
Shield Holdings AG (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage hospital pharmaceuticals, today announces that it has signed a strategic commercialisation agreement for its lead asset, ST10-021, an iron therapy product which has commenced Phase III clinical development, with AOP Orphan Pharmaceuticals AG.
Responding to a recent study showing that 40% of patients who receive CRT-ICD therapy do not benefit from the device (Sipahi, et al – 6/13/11), Wojciech Zareba, MD, PhD, stated that improving risk stratification of heart failure patients eligible for an implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with a defibrillator (CRT-D) is essential.
› Verified 2 days ago
Brian Christopher Smith, Radiology Medicare: Not Enrolled in Medicare Practice Location: 1649 Oak Leaf Ln, Belden, MS 38826 Phone: 662-507-8079 |